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SUMMARY
London, UK
SETTING: Thyolo district, Malawi.
OBJECTIVES: To determine in HIV-positive individuals
aged over 13 years CD4 lymphocyte counts in patients
classiﬁed as WHO Clinical Stage III and IV and patients
with active and previous tuberculosis (TB).
DESIGN: Cross-sectional study.
METHODS: CD4 lymphocyte counts were determined in
all consecutive HIV-positive individuals presenting to
the antiretroviral clinic in WHO Stage III and IV.
RESULTS: A CD4 lymphocyte count of <350 cells/ml
was found in 413 (90%) of 457 individuals in WHO
Stage III and IV, 96% of 77 individuals with active TB,
92% of 65 individuals with a history of pulmonary TB
(PTB) in the last year, 91% of 89 individuals with a pre-
vious history of PTB beyond 1 year, 81% of 32 individ-
uals with a previous history of extra-pulmonary TB, 93%
of 107 individuals with active or past TB with another
HIV-related disease and 89% of 158 individuals with
active or past TB without another HIV-related disease.
CONCLUSIONS: In our setting, nine of 10 HIV-positive
individuals presenting in WHO Stage III and IV and
with active or previous TB have CD4 counts of <350
cells/ml. It would thus be reasonable, in this or similar
settings where CD4 counts are unavailable for clinical
management, for all such patients to be considered eligible
for antiretroviral therapy.
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THE ACQUIRED immune-deficiency syndrome (AIDS)
is taking an appalling toll in Malawi, a small, impov-
erished country in Southern Africa. In 2003, it was es-
timated that there were 900 000 people living with
human immunodeﬁciency virus (HIV) and AIDS,
87000  AIDS-related deaths and 170 000 people in im-
mediate need of antiretroviral therapy (ART).1. How-
ever, in March 2004, only about 5000 people were
currently accessing ART.2 There is thus a desperate
need to rapidly scale up treatment.
Initiation of ART is usually based on a measure-
ment of the CD4 T-cell lymphocyte count, a labora-
tory test that acts as a ‘proxy’ for the immune status.
The World Health Organization (WHO) recommends
that ill HIV-positive persons who have a CD4 count
,350 cells/mm3 can be considered eligible for ART.3
However, this test is still expensive, the technology is
sophisticated, and in resource-limited settings, tying
the start of ART to a CD4 count measurement will act
as a constraint to scaling up treatment. Recognising
these difﬁculties, the WHO has recommended that
ART be given to all HIV-positive adults who are assessed
clinically as being in WHO Clinical Stage III and IV,
without the absolute requirement of a CD4 count.3
In this regard, tuberculosis (TB) poses a problem.
HIV-positive patients with active pulmonary tubercu-
losis (PTB) or a history of PTB in the previous year
are deﬁned as WHO Stage III, and those with extra-
pulmonary tuberculosis (EPTB) are deﬁned as Stage
IV.3 TB is a common HIV opportunistic infection in
sub-Saharan Africa, and it is likely that many HIV-
positive patients eligible for ART will have TB. How-
ever, HIV-positive patients in sub-Saharan Africa can
present with smear-positive PTB across a wide spec-
trum of CD4 counts.4,5 We were concerned that many
HIV-positive patients with TB might be started on
ART with CD4 counts .350 cells/mm3, and thus be
given treatment too early in the course of their HIV-
related illness.
Thyolo district in southern Malawi is one of the
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pioneer districts in Malawi where the feasibility of of-
fering ART in a routine programme setting is being as-
sessed. CD4 lymphocytes were systematically counted
in HIV-positive adults classiﬁed in WHO Stages III
and IV, including patients with active and previous
TB, to determine what proportion had CD4 counts . or
, 350 cells/mm3, and we now report on this audit.
METHODS
Study setting and patient assessments
The study was carried out between April 2003 and
January 2004 in Thyolo district, a rural region in
southern Malawi with a population of 450 000. The
main district hospital was the site of the study: this
hospital has integrated voluntary counselling and
HIV testing (VCT) units that have since 1999 offered
services to patients, mothers attending antenatal care
services and those who wish to know their HIV status.
HIV testing is conducted using rapid whole blood test
kits: Determine HIV-1/HIV-2 (Abbott Laboratories,
Tokyo, Japan) and Uni-GoldTM HIV-1/HIV-2 (Trinity
Biotech, Bray, Ireland), according to the WHO’s strat-
egy II for HIV antibody testing.6 Symptomatic HIV-
positive individuals undergo a complete medical as-
sessment for HIV-related diseases in the HIV clinic
and are categorised into different WHO stages accord-
ing to clinical ﬁndings.
ART and CD4 lymphocyte counts
ART, a ﬁxed-dose combination of stavudine, lamivu-
dine and nevirapine, is offered to patients in WHO
Stage III and IV once their HIV-related disease has
stabilised.7 CD4 lymphocyte counts are performed in
all these patients, usually a week before the planned
initiation of ART. CD4 lymphocyte counts were ini-
tially measured using a Coulter Cyto-Sphere CD4 Kit
(Coulter Corporation, Hialeah, FL, USA) at the Blan-
tyre Diagnostic Laboratories; since August 2003, CD4
lymphocytes have been counted using FacsCount®
(Beckton Dickinson, Immunocytometry Systems, San
Jose, CA, USA) at the John Hopkins Research Labora-
tory, Blantyre. Both laboratories are reference labora-
tories for the country, and they have strict quality
control standards. The two techniques used for CD4
estimation are internationally acceptable, robust and
are known to have a low average coefﬁcient of varia-
tion (4–6%).8,9
Study population and data collection
All HIV-positive individuals registered at the HIV/
ART clinic between April 2003 and January 2004
and in WHO Stage III or IV were included in the
study. Information on patients’ demographic charac-
teristics, WHO stage, CD4 count results and type of
HIV-related disease was entered into a speciﬁc data
collection sheet.
If a patient had active TB, the type of TB was
noted. If there was a past history of TB, speciﬁc in-
quiry was made about the type of TB, date of regis-
tration and initiation of anti-tuberculosis treatment
and the HIV status at the time of last TB diagnosis.
These data were veriﬁed through patient TB identity
cards and TB registers. Since mid-1999, all newly reg-
istered TB patients in Thyolo have been offered VCT,10
and from that period on HIV status could be veriﬁed
from the counselling registers. The current WHO stag-
ing system does not include individuals with a history
of PTB beyond the past year or individuals with EPTB
at any time in the past. In this study, HIV-positive in-
dividuals with a past history of PTB beyond 1 year
were classiﬁed into WHO Stage III or IV according to
the main HIV-related disease detected on initial clini-
cal examination. Individuals with no other HIV-related
disease except a past history of PTB beyond 1 year were
classiﬁed as WHO Stage III, and those with a past his-
tory of EPTB were classiﬁed as Stage IV, irrespec-
tive of whether or not they had any other HIV-related
disease.
Statistical analysis
Data were entered and analysed using Epi-Info soft-
ware (Centers for Disease Control and Prevention,
Atlanta, GA, USA). The level of conﬁdence was set at
95%, and 5% error was used throughout.
RESULTS
Characteristics of the study population
Of 506 HIV-positive individuals, 457 were aged .13
years and were involved in the study. They included
127 (28%) men and 330 (72%) women, with a me-
dian age of respectively 34 (range 14–64) and 33
years (range 15–64); 338 (74%) were classiﬁed in
WHO Stage III and 119 (26%) in Stage IV. Of these
patients, 265 (58%) had active or past TB: 77 (17%)
had active TB, 67 (15%) had a history of PTB in the
past year, 89 (19%) had a history of PTB that dated
beyond 1 year and 32 (7%) had a history of EPTB
at some time in the past; 192 (42%) individuals had
neither active TB nor a past history of TB.
CD4 proﬁle in relation to WHO staging
Table 1 shows the CD4 proﬁle in WHO Stage III or
IV individuals. Of these, 413 (90%) had a CD4 count
Table 1 CD4 lymphocyte counts in relation to WHO clinical 
staging of HIV infection and disease
CD4 ,200 
cells/ml
n (%)
200–350 
cells/ml
n (%)
.350 
cells/ml
n (%)
WHO Stage III (n 5 338) 232 (69) 77 (23) 29 (8)
WHO Stage IV (n 5 119) 84 (71) 20 (17) 15 (12)
Total 316 (69) 97 (21) 44 (10)
WHO 5 World Health Organization; HIV 5 human immunodeﬁciency virus.260 The International Journal of Tuberculosis and Lung Disease
<350 cells/ml, and 44 (10%) had .350 cells/ml. The
median count for all individuals was 140 cells/ml
(range 1–1314). In the 192 individuals with neither
active TB nor a past history of TB, 173 (90%) had a
CD4 count <350 cells/ml.
CD4 proﬁle in individuals with active TB
Individuals with active TB had a median CD4 count
of 133 cells/ml (range 1–715). The CD4 proﬁle in re-
lation to type of TB is shown in Table 2. Ninety-six
per cent of HIV-positive individuals with active TB
had a CD4 count <350 cells/ml.
CD4 proﬁle in individuals with a history 
of PTB during the past year
Table 3 shows the CD4 proﬁle in individuals with
PTB during the past year. The median count in this
group was 161 cells/ml (range 7–677), and 92% of all
individuals had a CD4 count <350 cells/ml. There
was no statistically signiﬁcant difference in the pro-
portion of individuals who had a CD4 count <350
cells/ml with regard to HIV status at the time of pre-
vious diagnosis of TB.
CD4 proﬁle in individuals with a history 
of PTB over 1 year
Eighty-nine individuals had a history of PTB over 1
year previously (median 3.2, range 1.3–6.6 years).
The median CD4 count in these patients was 153
cells/ml (range 5–1126). In 81 (91%), CD4 counts were
<350 cells/ml. HIV status was known at the time of
TB diagnosis in 40 (45%). Table 4 shows the CD4
counts in relation to whether or not the HIV status
was known at the time of last TB diagnosis. The dif-
ference between these two groups was not signiﬁcant.
Of the 89 individuals, 75 (84%) had another HIV-
related disease and 14 had no other HIV-related dis-
ease except previous PTB. Of those with another HIV-
related disease, 60 were classiﬁed as WHO Stage III
and 15 as Stage IV on the basis of the type of disease.
CD4 proﬁle and WHO staging in individuals with a 
history of EPTB at any time in the past
The median CD4 count in this group was 113 cells/ml
(range 19–1314); 81% of the 32 had a CD4 count
<350 cells/ml (Table 5). The median time between the
diagnosis of EPTB in the past and the present assess-
ment was 2.6 years (range 1.2–14).
CD4 proﬁle in relation to other HIV-related diseases 
in individuals with active TB and a past history 
of PTB or EPTB
The prevalence of HIV-related disease was signiﬁ-
cantly higher in individuals with a past history of PTB
Table 2 CD4 lymphocyte counts in HIV-positive individuals 
with a history of active tuberculosis (n 5 77)
CD4 ,200
cells/ml
n (%)
200–350
cells/ml
n (%)
.350
cells/ml
n (%)
TB type 
Smear-positive PTB (n 5 31) 25 (81) 5 (16) 1 (3)
Smear-negative PTB (n 5 30) 24 (80) 5 (17) 1 (3)
Extra-pulmonary TB (n 5 16)  11 (69) 4 (25) 1 (6)
Total 60 (78) 14 (18) 3 (4)
HIV 5 human immunodeﬁciency virus; TB 5 tuberculosis; PTB 5 pulmonary
tuberculosis.
Table 3 CD4 lymphocyte counts in individuals with a history 
of PTB in the previous 1 year and in relation to HIV status 
at the time of last TB diagnosis
CD4 ,200
cells/ml
n (%)
200–350
cells/ml
n (%)
.350
cells/ml
n (%)
HIV-positive at last TB diagnosis 23 (70) 9 (27) 1 (3)
Smear-positive PTB 15 4 1
Smear-negative PTB 8 5 0
HIV status unknown at last TB 
diagnosis  24 (75) 3 (9) 5 (16)
Smear-positive PTB 11 2 1
Smear-negative PTB 13 1 4
Total 47 (73) 12 (19) 6 (8)
PTB 5 pulmonary tuberculosis; HIV 5 human immunodeﬁciency virus; TB 5
tuberculosis.
Table 4 CD4 lymphocyte counts in individuals with a history 
of PTB more than 1 year ago and in relation to HIV status 
at the time of last TB diagnosis
CD4 ,200
cells/ml
n (%)
200–350
cells/ml
n (%)
.350
cells/ml
n (%)
HIV-positive at last TB diagnosis  28 (70) 9 (23) 3 (7)
Smear-positive PTB 17 7 2
Smear-negative PTB 11 2 1
HIV status unknown at last TB 
diagnosis  32 (65) 12 (24) 5 (10)
Smear-positive PTB 16 5 4
Smear-negative PTB 16 7 1
Total 60 (67) 21 (24) 8 (9)
PTB 5 pulmonary tuberculosis; HIV 5 human immunodeﬁciency virus; TB 5
tuberculosis.
Table 5 CD4 lymphocyte counts in individuals with a history 
of EPTB at any time in the past and in relation to HIV status 
at the time of last TB diagnosis
CD4 ,200
cells/ml
n (%)
200–350
cells/ml
n (%)
.350
cells/ml
n (%)
HIV status
Positive at last EPTB 
diagnosis (n 5 13) 7 (54) 3 (23) 3 (23)
Unknown at last EPTB 
diagnosis (n 5 19) 12 (63) 4 (21) 3 (16)
Total 19 (59) 7 (22) 6 (19)
EPTB  5 extra-pulmonary tuberculosis; HIV 5 human immunodeﬁciency
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over 1 year (87%) and with EPTB (56%) than in
those with active TB (8%) or a history of PTB during
the past year (12%). The CD4 proﬁles in relation to
these different groups are shown in Table 6. The ma-
jority of individuals with active TB or a past history
of PTB (during or beyond the past year) as well as
those with a history of EPTB at any time in the past
had CD4 counts <350 cells/ml, irrespective of whether
or not they had an HIV-related disease.
DISCUSSION
This study shows that if ART was initiated only on
clinical grounds, at least nine of 10 HIV-positive indi-
viduals in WHO Stage III and IV would have CD4
counts <350 cells/ml and would thus be eligible for
ART. The great majority of individuals with active TB
as well as a past history of PTB and EPTB would also
have CD4 counts <350 cells/ml, and would similarly
be eligible for ART. About 10% of those in our set-
ting had a CD4 count .350 cells/ml. In the absence of
routine CD4 counting, these cases would have started
ART at an earlier time than is usually recommended.
There were 188 individuals, 42% of those in WHO
Stage III and IV, who presented to the ART clinic with
a past history of TB; such patients appear to be a priv-
ileged group in terms of an entry-door to ART. Since
early 1999, all HIV-positive individuals, including TB
patients, have been integrated into a community
network of home-based care (HBC) volunteers and
nurses.10 This network ensures that individuals are
made aware of the link between TB and HIV and
are informed about ART eligibility. Individuals with
active and past TB are also encouraged to present to
the ART clinic. It is likely that our network of HBC
volunteers and nurses facilitated the selection and re-
ferral of individuals with a past history of TB to the
ART clinic, and the fact that 87 (46%) patients with
a past history of TB had no other HIV-related disease
on presentation supports the hypothesis that it is TB
that brought them to the clinic.
Individuals with a past history of PTB dating from
beyond 1 year and a history of EPTB at any time in
the past are not currently included in the WHO clas-
siﬁcation, and by strict deﬁnition they are not eligible
for ART.3 We think this should be re-examined. First,
we had documented evidence (through TB cards and
counselling registers) that nearly half (47%) of all in-
dividuals in these two groups were HIV-positive at the
time of their last TB diagnosis. If ART had been avail-
able at the time, they would in theory have been eligible
for ART and would have been started on treatment.
These individuals are also likely to have had a down-
hill progression in immune status since their last epi-
sode of TB, and the signiﬁcantly higher prevalence
of other HIV-related diseases in these two groups of
HIV-positive individuals is thus unsurprising. The
majority of individuals with a past history of PTB be-
yond 1 year and with EPTB at any time in the past
had a CD4 count <350 cells/ml. Second, HIV preva-
lence in TB patients in Thyolo is 77%,5 and close to
60% of all HIV individuals presenting in WHO Stage
III or IV had active TB or a past history of TB. It is
thus likely that TB is often what brings HIV-positive
individuals to medical attention. In such settings, it
would seem reasonable to think that a considerable
proportion of HIV-positive individuals with a past his-
tory of TB are likely to have been HIV-positive at the
time of their last TB diagnosis. Third, a past diagnosis
of TB is in practice a clear WHO deﬁning event that
can be veriﬁed through patient TB identity cards and
TB registers. In resource-poor settings such as ours,
this is often not the case with many other WHO Stage
III and IV clinical conditions.
This study supports WHO clinical staging as an
appropriate method for deciding whom to start on
ART. Reassuringly, the majority of HIV-positive pa-
tients with active or previous TB had low CD4 counts,
<350 cells/ml, and were thus eligible for ART based
on international criteria. This is useful for scaling up
ART in resource-limited settings such as Malawi,
where services will inevitably have to be provided
at lower levels of the health infrastructure to ensure
equitable access for the poor.
Acknowledgements
We are grateful to the Thyolo district hospital management and
particularly the National TB Control Programme in Malawi for
their excellent collaboration and encouragement in trying to imple-
ment joint TB-HIV activities, including ART in Thyolo. We are
Table 6 CD4 lymphocyte counts in relation to the presence 
or absence of an opportunistic infection in patients with
active TB or a past history of TB
CD4 ,200
cells/ml
n (%)
200–350
cells/ml
n (%)
.350
cells/ml
n (%)
Total
n (%)
Active TB (n 5 77)
Opportunistic
infection present 5 (83) 1 (17) 0 6 (8)
Opportunistic 
infection absent 55 (78) 13 (18) 3 (4) 71 (92)
PTB ,1 year (n 5 67) 
Opportunistic
infection present 6 (75) 2 (25) 0 8 (12)
Opportunistic 
infection absent 41 (70) 10 (17) 8 (13) 59 (88)
PTB .1 year (n 5 89)
Opportunistic 
infection present 56 (75) 15 (20) 4 (5) 75 (84)
Opportunistic 
infection absent 4 (29) 6 (43) 4 (29) 14 (16)
EPTB at any time in 
the past (n 5 32)
Opportunistic 
infection present 10 (56) 4 (22) 4 (22) 18 (56)
Opportunistic 
infection absent 9 (64) 3 (21) 2 (14) 14 (44)
TB 5 tuberculosis; PTB 5 pulmonary tuberculosis; EPTB 5 extra-pulmonary
tuberculosis.262 The International Journal of Tuberculosis and Lung Disease
also grateful to the National AIDS Commission for their continued
support. We are grateful to Dr Peter Firminish for having reviewed
the manuscript and for his useful comments.
The joint TB-HIV support programme, including ART, is
supported by Médecins sans Frontières (Brussels Operational
Centre).
The views expressed in this article are those of the authors
alone and do not necessarily reﬂect the stated policy of the WHO.
References
1 Ministry of Health and Population. National AIDS Commis-
sion of Malawi. National estimate of HIV/AIDS in Malawi.
Lilongwe, Malawi: Ministry of Health and Population, 2003.
2 Chimzizi R, Harries A, Libamba E, et al. Report of a country-
wide survey of HIV/AIDS services in Malawi (for the year
2003). National Tuberculosis Control Programme and HIV/
AIDS Unit, Ministry of Health, and National AIDS Commis-
sion. Lilongwe, Malawi: Ministry of Health and Population,
April 2004.
3 World Health Organization. Scaling up anti-retroviral therapy
in resource-limited settings. Treatment guidelines for a public
health approach. QV268.5 revised version. Geneva, Switzer-
land: WHO, 2003.
4 Mukadi Y, Perriens J H, St Louis M E, et al. Spectrum of
immunedeﬁciency in HIV-1 infected patients with pulmonary
tuberculosis in Zaire. Lancet 1993; 342: 143–146.
5 Ackah A N, Coulibaly D, Digbeu H, et al. Response to treat-
ment, mortality, and CD4 lymphocyte counts in HIV-infected
persons with tuberculosis in Abidjan, Cote d’Ivoire. Lancet
1995; 345: 607–610.
6 Revised recommendations for the selection and use of HIV
antibody tests Wkly Epidemiol Rec 1997; 72: 81–87.
7 Ministry of Health and Population and National AIDS Com-
mission. Guidelines for the use of anti-retroviral therapy in
Malawi. 1st ed. Lilongwe, Malawi: UNAIDS/WHO, 2003.
8 Johnson D, Hirschkorn D, Busch M P. Evaluation of four al-
ternative methods for determination of absolute CD41 lym-
phocyte counts. The National Heart, Lung and Blood Institute
Retrovirus Epidemiology Donor Study. J Acquir Immune Deﬁc
Syndr Hum Retrovirol 1995; 15: 522–530.
9 Sherman G G, Galpin G S, Patel J M, Mendelow B V, Glencross
D K. CD41 T cell enumeration in HIV infection in countries with
limited resources. J Immunol Methods 1999; 222: 209–217.
10 Zachariah R, Spielmann M P, Chingi C, et al. Voluntary coun-
seling, HIV testing and adjunctive cotrimoxazole reduces mor-
tality in tuberculosis patients in Thyolo, Malawi. AIDS 2003;
17:1053–1061.
RÉSUMÉ
CONTEXTE: District de Thyolo au Malawi.
OBJECTIFS: Déterminer les décomptes de lymphocytes
CD4 chez les patients séropositifs pour le VIH, âgés de
plus de 13 ans et classifiés comme stades III et IV de la
classification clinique de l’OMS et chez les patients at-
teints de tuberculose (TB) active ou antérieure.
SCHÉMA : Etude transversale.
MÉTHODES: Les décomptes de lymphocytes CD4 ont
été faits chez tous les individus consécutifs séropositifs
pour le VIH aux stades III et IV de l’OMS, se présentant
dans une polyclinique antirétrovirale
RÉSULTATS: On a trouvé un décompte de lymphocytes
CD4 de <350 cellules/mL chez 413 (90%) des 457 indi-
vidus aux stades III et IV de l’OMS, chez 96% de 77 in-
dividus atteints de TB active, chez 92% des 65 individus
avec des antécédents de tuberculose pulmonaire (TBP)
au cours de la dernière année, chez 91% des 89 individus
ayant des antécédents de TBP remontant à plus d’un an,
chez 81% des 32 individus avec une anamnèse de TB
extrapulmonaire, chez 93% de 107 individus atteints
d’une TB active ou stabilisée et qui étaient atteints d’une
autre maladie en relation avec le VIH et chez 89% de
158 individus atteints d’une TB active ou stabilisée mais
sans autre maladie en relation avec le VIH.
CONCLUSIONS: Dans notre contexte, neuf sur 10 indi-
vidus séropositifs pour le VIH se présentant aux stades
III et IV de l’OMS ou avec une TB active ou antérieure ont
des décomptes de lymphocytes CD4 <350 cellules/mL. Il
serait dès lors raisonnable dans des contextes similaires où
les décomptes de CD4 ne sont pas disponibles de considé-
rer dans la prise en charge clinique l’ensemble de ces pa-
tients comme éligibles pour le traitement antirétroviral.
RESUMEN
MARCO DE REFERENCIA: El distrito de Thyolo, Malawi.
OBJETIVOS: Determinar el recuento de linfocitos CD4
en pacientes mayores de 13 años con serología positiva
para el VIH que se encuentran en estadio clínico III o IV
según la clasificación de la OMS, y en pacientes con
tuberculosis (TB) activa o con antecedente de TB.
DISEÑO DEL ESTUDIO: Estudio transversal.
MÉTODOS: Se determinó el recuento de linfocitos CD4
en todos los individuos seropositivos que se presentaron
en estadios III o IV de la OMS al consultorio de trata-
miento antirretrovírico.
RESULTADOS: Se observó un recuento de linfocitos
CD4  <350 células/ml en 413 de los 457 pacientes (90%)
en estadios III o IV de la OMS, en el 96% de los 77 in-
dividuos con TB activa, en el 92% de los 65 individuos
con antecedente de TB pulmonar en el último año, en el
91% de los 89 pacientes con antecedente de más de 1
año de TB pulmonar, en el 81 % de los 32 individuos
con antecedente de TB extrapulmonar, en el 93 % de los
107 individuos con antecedente de TB o con TB activa
con otra enfermedad relacionada con la infección por el
VIH y en el 89 % de los 158 pacientes con antecedente
de TB o con TB activa sin otra enfermedad relacionada
con la infección por el VIH.
CONCLUSIONES: En nuestro medio, nueve de cada 10
individuos seropositivos que acuden en estadio clínico
III o IV de la OMS con TB activa o antecedente de TB
tienen recuentos de CD4 <350 células/ml. En este con-
texto, o en ambientes similares donde no se dispone del
recuento de CD4 para el manejo clínico, sería razonable
considerar todos estos pacientes idóneos para trata-
miento antirretrovírico.